Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patientsSamantha Pozzi, On behalf of the Gruppo Italiano St, Pellegrino Musto et al.|Leukemia & lymphoma/Leukemia and lymphoma|2006Cited by 93
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Luciano Masini, Raffaella Marcheselli et al.|Leukemia & lymphoma/Leukemia and lymphoma|2011Cited by 28
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.Samantha Pozzi, Giuseppe Pollastri, Raffaella Marcheselli et al.|Blood|2005Cited by 26
Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on HclFrancesco Forconi, Francesco Lauria, Emanuele Cencini et al.|Blood|2010Cited by 8
Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)Francesco Forconi, Francesco Lauria, Emanuele Cencini et al.|Blood|2010Cited by 0